5 Key Insights On The Pulmonary Arterial Hypertension Market 2023
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
As per The Business Research Company’s Pulmonary Arterial Hypertension Global Market Report 2023, the pulmonary arterial hypertension market is expected to show significant growth in the forecast period.
Key insights from the pulmonary arterial hypertension market forecast include:
- Market Size
The global pulmonary arterial hypertension market is expected to grow from $7.05 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The pulmonary arterial hypertension market size is expected to grow to $10.47 billion in 2027 at a CAGR of 8.2%.
- Major Driver
The rising prevalence of pulmonary arterial hypertension (PAH) condition is fueling the pulmonary arterial hypertension market. During the projected period, the rising prevalence of PAH disorders and the associated hospitalisation of patients for treatment are expected to drive up demand for relevant medications. According to a study published by the National Organisation for Rare Disorders, Inc., new instances of PAH are projected to occur in one to two people per million in the United States each year, equating to 500-1000 new cases per year, with Europe expected to have comparable incidence rates.
View More On The Pulmonary Arterial Hypertension Market Report 2023 – https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report
- Key Trend
Technological developments are important trends that are gaining traction in the pulmonary arterial hypertension market. Companies in the pulmonary arterial hypertension drug business are concentrating on the development of novel medicines to improve and cure these conditions. For example, in April 2021, United Therapeutics Corporation, a biotechnology company based in the United States, will commercialise Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that assists patients with improving their exercise abilities, decreasing respiratory difficulties, having a low tolerance for exertion, and having a higher mortality rate.
- Largest Region
North America was the largest region in the pulmonary arterial hypertension market in 2022.
- Major Players
Major players in the food diagnostics market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc., Natco Pharma Ltd., Zydus Pharmaceutical USA, and Liquidia Technologies Inc.
Request A Sample Of The Global Pulmonary Arterial Hypertension Market Report 2023:
Key Pulmonary Arterial Hypertension Market Segments
The global pulmonary arterial hypertension market is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
The Pulmonary Arterial Hypertension Global Market Report 2023 provides an in-depth analysis on the pulmonary arterial hypertension market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Follow us on:
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model